An Improved Score for the Evaluation of Mucosal Healing in Inflammatory Bowel Disease—A Pilot Study
暂无分享,去创建一个
C. Silaghi | A. Crăciun | T. Drugan | L. Ciobanu | C. Drugan | Lidia Neamți
[1] C. Matei,et al. Correlation of Biomarkers with Endoscopic Score: Ulcerative Colitis Endoscopic Index of Severity (UCEIS) in Patients with Ulcerative Colitis in Remission , 2020, Medicina.
[2] Mariusz A. Bromke,et al. Biochemical Biomarkers of Mucosal Healing for Inflammatory Bowel Disease in Adults , 2020, Diagnostics.
[3] B. Click,et al. The burden of cost in inflammatory bowel disease: a medical economic perspective. , 2020, Current opinion in gastroenterology.
[4] S. Vermeire,et al. The Ulcerative Colitis Response Index for Detection of Mucosal Healing in Patients Treated With Anti-tumour Necrosis Factor. , 2020, Journal of Crohn's & colitis.
[5] J. Feuerstein,et al. Colorectal cancer surveillance in inflammatory bowel disease: Practice guidelines and recent developments , 2019, World journal of gastroenterology.
[6] J. Stoker,et al. ECCO-ESGAR Guideline for Diagnostic Assessment in IBD Part 2: IBD scores and general principles and technical aspects. , 2018, Journal of Crohn's & colitis.
[7] Shan Gao,et al. Efficacy of noninvasive evaluations in monitoring inflammatory bowel disease activity: A prospective study in China , 2017, World journal of gastroenterology.
[8] Jana G Hashash,et al. A comprehensive review and update on Crohn's disease. , 2017, Disease-a-month : DM.
[9] M. Barreiro-de Acosta,et al. Accuracy of Consecutive Fecal Calprotectin Measurements to Predict Relapse in Inflammatory Bowel Disease Patients Under Maintenance With Anti-TNF Therapy: A Prospective Longitudinal Cohort Study , 2016, Journal of clinical gastroenterology.
[10] E. de Boer,et al. High Percentage of IBD Patients with Indefinite Fecal Calprotectin Levels: Additional Value of a Combination Score , 2016, Digestive Diseases and Sciences.
[11] Steven J Brown,et al. Cost-effectiveness of Crohn's disease post-operative care. , 2016, World journal of gastroenterology.
[12] T. Voiosu,et al. Rapid fecal calprotectin level assessment and the SIBDQ score can accurately detect active mucosal inflammation in IBD patients in clinical remission: a prospective study. , 2014, Journal of gastrointestinal and liver diseases : JGLD.
[13] M. Färkkilä,et al. Mucosal healing at 3 months predicts long-term endoscopic remission in anti-TNF-treated luminal Crohn's disease , 2013, Scandinavian journal of gastroenterology.
[14] M. Färkkilä,et al. Surrogate markers and clinical indices, alone or combined, as indicators for endoscopic remission in anti-TNF-treated luminal Crohn's disease , 2012, Scandinavian journal of gastroenterology.
[15] J. Jahnsen,et al. Fecal calprotectin variability in Crohn's disease. , 2010, Inflammatory bowel diseases.
[16] A. Schoepfer,et al. Fecal Calprotectin Correlates More Closely With the Simple Endoscopic Score for Crohn's Disease (SES-CD) than CRP, Blood Leukocytes, and the CDAI , 2010, The American Journal of Gastroenterology.
[17] J. Ellenberg,et al. Use of the noninvasive components of the mayo score to assess clinical response in Ulcerative Colitis , 2008, Inflammatory bowel diseases.
[18] A. Michalsen,et al. Noninvasive Markers in the Assessment of Intestinal Inflammation in Inflammatory Bowel Diseases: Performance of Fecal Lactoferrin, Calprotectin, and PMN-Elastase, CRP, and Clinical Indices , 2008, The American Journal of Gastroenterology.
[19] R. Xavier,et al. Unravelling the pathogenesis of inflammatory bowel disease , 2007, Nature.
[20] J. Satsangi,et al. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. , 2005, Canadian journal of gastroenterology = Journal canadien de gastroenterologie.
[21] S. Fais,et al. The clinical significance of serum C reactive protein levels in Crohn's disease. Results of a prospective longitudinal study. , 1988, Journal of clinical gastroenterology.